Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
254 studies found for:    regeneron
Hide Display Options

Display Options

Study Details
Participant Details
Rank Status Study
1 Recruiting Study to Evaluate the Efficacy and Safety of REGN2222, for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants
Condition: Respiratory Syncytial Virus Infections
Interventions: Drug: REGN2222;   Drug: Placebo
2 Recruiting Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection
Condition: Neovascular Age-Related Macular Degeneration
Interventions: Drug: REGN910-3;   Drug: Intravitreal Aflibercept Injection (IAI)
3 Completed
Has Results
Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)
Condition: Macular Edema Secondary to Central Retinal Vein Occlusion
Interventions: Biological: VEGF Trap-Eye 2.0mg;   Drug: Sham
4 Enrolling by invitation A Study to Assess the Long-term Safety of Dupilumab (REGN668/SAR231893) Administered in Patients 6 to <18 Year of Age With Atopic Dermatitis (AD)
Condition: Atopic Dermatitis
Intervention: Drug: Dupilumab
5 Completed A Study to Evaluate the Safety and Efficacy of Subcutaneously Administered REGN475(SAR164877) in Patients With Sciatic Pain
Condition: Sciatica
Interventions: Drug: REGN475;   Drug: Placebo Injection
6 Completed Open Label, Drug-Drug Interaction (DDI) Study of Dupilumab (REGN668/SAR231893) in Patients With Moderate to Severe Atopic Dermatitis (AD)
Condition: Atopic Dermatitis
Interventions: Drug: Dupilumab;   Drug: Midazolam;   Drug: Omeprazole;   Drug: Warfarin;   Drug: Caffeine;   Drug: Metoprolol
7 Completed Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Condition: Dermatitis, Atopic
Interventions: Drug: dupilumab;   Drug: placebo
8 Completed Safety and Tolerability of Intravitreal VEGF Trap Formulations in Subjects With Neovacular AMD
Condition: Neovascular Age Related Macular Degeneration
Interventions: Drug: VEGF Trap;   Biological: VEGF Trap
9 Withdrawn A Study of the Safety and Efficacy of Subcutaneously Administered REGN475 in Patients With Osteoarthritis of the Knee
Condition: Osteoarthritis
Interventions: Biological: REGN475;   Other: Placebo
10 Withdrawn Study of the Safety and Efficacy of REGN475(SAR164877) in Patients With Pain Resulting From Thermal Injury
Condition: Thermal Injury Pain
Interventions: Drug: R475;   Drug: Placebo
11 Withdrawn Study of the Safety and Effectiveness of Rilonacept (IL-1 Trap) Administered Subcutaneously in Subjects With Non Dialysis-Dependent Chronic Kidney Disease (NDD-CKD) and Anemia
Conditions: Chronic Kidney Disease;   Anemia
Intervention: Drug: Rilonacept
12 Completed Phase 1 Study of VEGF Trap in Patients With Diabetic Macular Edema
Condition: Diabetic Macular Edema
Intervention: Drug: VEGF Trap-Eye
13 Recruiting Study of Safety, Tolerability, and Pharmacokinetics of REGN3470-3471-3479 in Healthy Adult Volunteers
Condition: Healthy Volunteers
Interventions: Drug: REGN3470-3471-3479;   Drug: Placebo
14 Recruiting Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell Carcinoma
Condition: Advanced Cutaneous Squamous Cell Carcinoma
Intervention: Drug: REGN2810
15 Recruiting A Study to Assess the Efficacy and Safety of Dupilumab in Patients With Severe Atopic Dermatitis (AD) That Are Not Controlled With Oral Cyclosporine A (CSA) or for Those Who Cannot Take Oral CSA Because it is Not Medically Advisable
Condition: Atopic Dermatitis
Interventions: Drug: Dupilumab;   Drug: Placebo
16 Recruiting Study of the Efficacy and Safety of Intravitreal (IVT) Aflibercept for the Improvement of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy (NPDR)
Condition: Nonproliferative Diabetic Retinopathy
Interventions: Drug: Intravitreal aflibercept injection [IAI];   Drug: Sham
17 Recruiting Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema
Condition: Diabetic Macular Edema
Interventions: Drug: REGN910-3;   Drug: Intravitreal Aflibercept Injection (IAI)
18 Recruiting Long-Term Safety and Efficacy Study of Fasinumab in Patients With Pain Due to Osteoarthritis (OA) of the Knee or Hip
Condition: Osteoarthritis of the Knee or Hip
Interventions: Drug: Fasinumab;   Drug: Placebo
19 Recruiting Study of REGN2810 and REGN1979 in Patients With Lymphoma or Acute Lymphoblastic Leukemia
Conditions: Lymphoma;   Acute Lymphoblastic Leukemia
Interventions: Drug: REGN2810;   Drug: REGN1979
20 Recruiting A Study to Determine the Efficacy and Safety of Fasinumab for the Treatment of Adults With Chronic Low Back Pain
Condition: Low Back Pain
Interventions: Drug: Fasinumab;   Drug: placebo

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years